All In Biotech

Drug Trial Radar · NCT05466422

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

A Multiple Ascending Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

34

Actual

Start

Sep 20, 2022

Primary completion

Jul 3, 2025

Study completion Jul 3, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease. The primary hypothesis (Part 1) is that at a generally well-tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is \>0.3 nanomolar

Conditions

  • Alzheimer Disease

Interventions

  • MK-2214Biological

    IV infusion

  • PlaceboDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 297 days
  2. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 57 days
  3. Area Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of MK-2214 in Serum After First Dose (Day 1)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
  4. AUC0-28 of MK-2214 in Serum After Third Dose (Day 57)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
  5. Maximum Serum Concentration (Cmax) of MK-2214 After First Dose (Day 1)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
  6. Cmax of MK-2214 After Third Dose (Day 57)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
  7. Time of Maximum Serum Concentration (Tmax) of MK-2214 After First Dose (Day 1)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
  8. Tmax of MK-2214 After Third Dose (Day 57)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
  9. Apparent Half-Life (T1/2) of MK-2214 in Serum After Third Dose (Day 57)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
  10. Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85Time frame: Day 85
  11. Free Phospho-Tau Concentration in CSFTime frame: Day 85

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0007)

    Glendale, California

  • Collaborative Neuroscience Research, LLC ( Site 0009)

    Los Alamitos, California

  • NRC Research Institute ( Site 0015)

    Orange, California

  • Velocity Clinical Research, Hallandale Beach ( Site 0001)

    Hallandale, Florida

  • Research Centers of America ( Hollywood ) ( Site 0004)

    Hollywood, Florida

  • K2 Medical Research ( Site 0005)

    Maitland, Florida

  • Charter Research - Winter Park ( Site 0012)

    Orlando, Florida

  • Progressive Medical Research-Alzheimer's Team ( Site 0013)

    Port Orange, Florida

  • Charter Research - Lady Lake ( Site 0011)

    The Villages, Florida

  • CenExel iResearch, LLC ( Site 0002)

    Decatur, Georgia

  • Global Medical Institutes LLC; Princeton Medical Institute ( Site 0003)

    Princeton, New Jersey

  • Neuro-Behavioral Clinical Research ( Site 0016)

    North Canton, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.